- Home
- CANF vs CLDI Comparison
CANF vs CLDI Comparison
Compare CANF & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- CLDI
- Stock Information
- Founded
- CANF 1994
- CLDI 2014
- Country
- CANF Israel
- CLDI United States
- Employees
- CANF N/A
- CLDI N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CANF Health Care
- CLDI Health Care
- Exchange
- CANF Nasdaq
- CLDI Nasdaq
- Market Cap
- CANF 14.8M
- CLDI 15.7M
- IPO Year
- CANF N/A
- CLDI N/A
- Fundamental
- Price
- CANF $1.04
- CLDI $0.40
- Analyst Decision
- CANF Strong Buy
- CLDI Strong Buy
- Analyst Count
- CANF 2
- CLDI 2
- Target Price
- CANF $14.00
- CLDI $15.00
- AVG Volume (30 Days)
- CANF 172.6K
- CLDI 202.0K
- Earning Date
- CANF 05-27-2025
- CLDI 05-20-2025
- Dividend Yield
- CANF N/A
- CLDI N/A
- EPS Growth
- CANF N/A
- CLDI N/A
- EPS
- CANF N/A
- CLDI N/A
- Revenue
- CANF $674,000.00
- CLDI N/A
- Revenue This Year
- CANF $461.72
- CLDI N/A
- Revenue Next Year
- CANF N/A
- CLDI N/A
- P/E Ratio
- CANF N/A
- CLDI N/A
- Revenue Growth
- CANF N/A
- CLDI N/A
- 52 Week Low
- CANF $1.02
- CLDI $0.35
- 52 Week High
- CANF $4.69
- CLDI $4.90
- Technical
- Relative Strength Index (RSI)
- CANF 37.30
- CLDI 36.62
- Support Level
- CANF $0.98
- CLDI $0.40
- Resistance Level
- CANF $1.14
- CLDI $0.46
- Average True Range (ATR)
- CANF 0.06
- CLDI 0.04
- MACD
- CANF 0.01
- CLDI 0.00
- Stochastic Oscillator
- CANF 32.59
- CLDI 9.73
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.